- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05911217
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
August 14, 2023 updated by: CARsgen Therapeutics Co., Ltd.
An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer
An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is an open, multicenter, Phase Ib clinical trial evaluating chimeric antigen receptor-modified autologous T cells targeting Claudin18.2
(CLDN18.2) (CT041 autologous CAR T) in subjects with CLDN18.2 expression-positive pancreatic cancer who has undergone adjuvant chemotherapy.
The aim of this study is to evaluate the efficacy, safety of CT041 treatment.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lifeng Zhang
- Phone Number: 86-21-54489928
- Email: lifengzhang@carsgen.com
Study Contact Backup
- Name: Ning Wang
- Phone Number: 86-21-54489926
- Email: ningwang@carsgen.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China
- Not yet recruiting
- Henan Cancer Hospital
-
Contact:
- Xiaobing Chen, Ph.D
- Email: zlyychenxb0807@zzu.edu.cn
-
-
Hubei
-
Wuhan, Hubei, China
- Not yet recruiting
- Union Hospital, Tongji Medical College, Hua zhong University of Science and Technology
-
Contact:
- Heshui Wu, Ph.D
- Email: heshuiwu@hust.edc.cn
-
-
Hunan
-
Changsha, Hunan, China
- Recruiting
- Hunan Provincial People's Hospital
-
Contact:
- Wei Cheng, Ph.D
- Email: 13974866177@163.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Not yet recruiting
- Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine
-
Contact:
- Jun Zhang, Ph.D
- Email: junzhang@188.com
-
Shanghai, Shanghai, China, 201321
- Recruiting
- Fudan University Shanghai Cancer Hospital
-
Contact:
- Xianjun Yu, Ph.D
- Phone Number: 02164175590
- Email: yuxianjun@fudanpci.org
-
Contact:
- Jian Zhang, Ph.D
- Phone Number: 02164175590
- Email: Syner2000@163.com
-
-
Shanxi
-
Xian, Shanxi, China
- Recruiting
- The First Affiliated Hospital of Xi'An JiaoTong University
-
Contact:
- Zheng Wu
- Email: woozheng@xjtu.edu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Zhejiang Provincial People's Hospital
-
Contact:
- Yiping Mou, Ph.D
- Email: yipingmou@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able to complete all study procedures;
- Aged 18 to 79 years;
- Histologically confirmed pancreatic ductal adenocarcinoma;
- Macroscopic complete tumor removal (R0 or R1 resection);
- Postoperative pathological stage (pTNM): T1-3, N0-2, M0;
- Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive;
- Subjects had recovered from surgery and had received 3 months of standard adjuvant therapy;
- Abnormal CA19-9 level;
- With sufficient venous access for leukapheresis collection;
- ECOG performance status score 0-1;
- Adequate organ function;
- Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;
Exclusion Criteria:
- Prior neoadjuvant therapy for pancreatic cancer;
- Subjects with borderline resectable pancreatic cancer;
- Present or past history of metastatic or locally recurrent pancreatic cancer;
- Evidence of malignant ascites;
- Subjects had diseases that may interfere with CA19-9 level, including but not limited to cholangitis, pancreatitis, obstructive jaundice, etc.
- Toxicities caused by previous treatment have not recovered to CTCAE ≤ grade 2, except alopecia and other tolerable events as judged by the investigator or laboratory abnormalities allowed in this study;
- Pregnant or lactating women;
- Positive serology for HIV, Treponema pallidum or HCV;
- Any active infections, including but not limited to active tuberculosis, HBV, EBV, CMV, COVID-19 infections;
- Clinically significant thyroid dysfunction;
- Previous allergy to immunotherapy and related drugs, allergy to CT041 ingredients and other serious allergic history;
- Subjects who may be at high risk for potential digestive tract bleeding or perforation;
- Known active autoimmune disease, including but not limited to, psoriasis or rheumatoid arthritis, or other conditions requiring long-term immunosuppressive therapy;
- Subjects who have a history of organ transplantation or are awaiting organ transplantation;
- Subjects who require anticoagulant therapy;
- Subjects who are receiving or are expected to require long-term antiplatelet therapy during the study;
- Subjects who have experienced major surgery or have significant trauma within 4 weeks before apheresis, or who are expected to undergo major surgery during the study period;
- Previously received any gene-modified cell therapies (including CAR T, TCR T);
- Subjects who have other serious diseases that may restrict them from participating in the study assessed by investigators;
- Subjects with oxygen saturation ≤ 95%;
- Subjects who have signs of central nervous system diseases or clinically significant neurological examination abnormalities;
- Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin;
- Vaccination with live attenuated vaccines within 4 weeks prior to apheresis or planned during the study;
- Subjects who are unable to or unwilling to comply with the requirements of the study protocol as assessed by investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: anti-claudin18.2 chimeric antigen receptor T-cell therapy
Experimental: anti-claudin18.2
chimeric antigen receptor T-cell therapy Phase 1b: Evaluate the efficacy and safety of CT041
|
Treatment with anti-claudin18.2
chimeric antigen receptor T-cell infusion.
Up to 3 times CT041 autologous CAR T-cell injection infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free survival (DFS)
Time Frame: Up to 18 months
|
The time from the first infusion to the occurrence of local recurrence/distant metastasis or death from any cause, whichever occurred first.
|
Up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment Related adverse events (AEs), treatment related AEs, AEs of special interest (AESI).
Time Frame: Up to 18 months
|
An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
|
Up to 18 months
|
1 year DFS rate
Time Frame: Up to 18 months
|
Proportion of patients alive without local recurrence/distant metastasis 1 year after the first infusion.
|
Up to 18 months
|
Metastasis free Survival (MFS)
Time Frame: Up to 18 months
|
The time from the first infusion to the occurrence of any pancreatic cancer distant metastases or death from any cause, whichever occurred first.
|
Up to 18 months
|
Overall Survival (OS)
Time Frame: Up to 18 months
|
The time from the first infusion to death of the subject from any cause.
|
Up to 18 months
|
The phamacokinetics in subjects receiving CT041 infusion in this study
Time Frame: Up to 18 months
|
Peak cell expansion, peak expansion, area under the curve (AUC), and duration of cell survival after infusion of CT041 cells.
|
Up to 18 months
|
The immunogenicity in subjects receiving CT041 infusion in this study
Time Frame: Up to 18 months
|
Drug antibody (ADA) positive rate after infusion of CT041 cells.
|
Up to 18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Xianjun Yu, Ph.D, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 11, 2023
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
June 12, 2023
First Submitted That Met QC Criteria
June 12, 2023
First Posted (Actual)
June 20, 2023
Study Record Updates
Last Update Posted (Actual)
August 16, 2023
Last Update Submitted That Met QC Criteria
August 14, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT041-ST-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
Clinical Trials on CT041 autologous CAR T-cell injection
-
Peking UniversityCARsgen Therapeutics Co., Ltd.RecruitingPancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaChina
-
The Affiliated Hospital of Qingdao UniversityNot yet recruitingDiffuse Large B Cell Lymphoma
-
Suzhou Immunofoco Biotechnology Co., LtdRecruitingAdvanced Digestive System TumorChina
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Beijing GoBroad HospitalRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic LeukemiaChina
-
Zhu XiaofanRecruitingB Lymphoblastic Lymphoma | B Lymphocytic LeukemiaChina
-
The First Affiliated Hospital of Soochow UniversityShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...RecruitingLymphoma, B-Cell | Autologous Stem Cell TransplantationChina
-
John ListerMiltenyi Biotec, Inc.; Lentigen Technology, Inc.; AHN (Allegheny Health Network)...RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | B Acute Lymphoblastic Leukemia | B-Cell Lymphoma | Transformed LymphomaUnited States
-
Kang YUCARsgen Therapeutics Co., Ltd.Active, not recruitingHepatocellular Carcinoma | B Cell Lymphoma | Pancreatic Carcinoma | Myeloma | B Cell Leukemia | Adenocarcinoma of Esophagogastric JunctionChina